Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC

INTRODUCTION: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent durvalumab therapy, data on the effect of TRL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuge, Tomoki, Shiroyama, Takayuki, Tamiya, Akihiro, Tamiya, Motohiro, Kanazu, Masaki, Kinehara, Yuhei, Tanaka, Tsunehiro, Morimura, Osamu, Taniguchi, Yoshihiko, Niki, Toshie, Tetsumoto, Satoshi, Hayashi, Kazuhiko, Nishino, Kazumi, Nagatomo, Izumi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239913/
https://www.ncbi.nlm.nih.gov/pubmed/37284296
http://dx.doi.org/10.1016/j.jtocrr.2023.100505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239913/
https://www.ncbi.nlm.nih.gov/pubmed/37284296
http://dx.doi.org/10.1016/j.jtocrr.2023.100505

Ejemplares similares